Spravato®

• Proven effective for Treatment-Resistant Depression and is FDA-approved

• If two or more oral antidepressants haven’t worked for you, adding Spravato® may be able to help.

Spravato Patient Stories

• Greater reduction of depression symptoms at four weeks (compared to those who received a placebo and oral antidepressant)

• For the first time in 60 years, we have a new antidepressant therapy that isn’t just a spinoff of existing drugs,” - Adam Kaplin, M.D., Ph.D., - psychiatrist with Johns Hopkins Medicine.

What is Spravato?®

SPRAVATO® is the only FDA-approved nasal spray for treatment-resistant depression (TRD) and is covered by insurance. It is an N-methyl-D aspartate (NMDA) receptor antagonist and is believed to work differently than currently available oral antidepressants. It increases the level of glutamate in the brain which is the most abundant neurotransmitter (chemical messenger) in the brain. Glutamate is important to memory, cognition, and mood regulation.

Indications of Use

SPRAVATO® is a controlled prescription medicine, used along with an oral antidepressant to treat:

• Adults with treatment-resistant depression (TRD)

• Major depressive disorder (MDD) with acute suicidal ideation or behavior

How is the treatment administered?

Spravato® treatments are done at VividLife Clinic which is a Spravato® certified treatment facility. You self administer the nasal spray under the supervision of a healthcare provider in our private and comfortable treatment rooms. You will be monitored during and after the treatment for approximately two hours. You will need to arrange for transportation to safely get home.

How often will the treatment be?

Treatment-resistant depression (TRD)

Major depressive disorder (MDD)
Major depressive disorder (MDD) with acute suicidal ideation or behavior

Watch the video below to find out more

Are there side effects?

Most side effects occur within one to two hours after the medication has been administered. For the safety of patients, the clinic will closely monitor each patient for approximately two hours following the administration of the medication before they can go home. These side effects include: